Natixis Advisors LLC Grows Stock Holdings in Sanofi $SNY

Natixis Advisors LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 11.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,113,381 shares of the company’s stock after purchasing an additional 327,569 shares during the period. Natixis Advisors LLC owned about 0.13% of Sanofi worth $146,952,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Caprock Group LLC purchased a new stake in shares of Sanofi during the third quarter valued at about $1,347,000. Assetmark Inc. increased its stake in Sanofi by 25.0% during the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock valued at $16,859,000 after purchasing an additional 71,356 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in Sanofi by 10,152.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock valued at $103,846,000 after purchasing an additional 2,178,647 shares in the last quarter. NewEdge Wealth LLC raised its holdings in shares of Sanofi by 63.1% in the third quarter. NewEdge Wealth LLC now owns 67,303 shares of the company’s stock worth $3,298,000 after buying an additional 26,035 shares during the last quarter. Finally, Willis Investment Counsel raised its stake in Sanofi by 11.3% in the 3rd quarter. Willis Investment Counsel now owns 556,700 shares of the company’s stock worth $26,276,000 after acquiring an additional 56,500 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Trading Down 1.0%

Shares of Sanofi stock opened at $44.55 on Friday. The stock has a 50 day moving average of $47.31 and a 200 day moving average of $48.46. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. The firm has a market capitalization of $108.66 billion, a price-to-earnings ratio of 12.38, a PEG ratio of 1.15 and a beta of 0.45. Sanofi has a fifty-two week low of $44.00 and a fifty-two week high of $60.12.

Wall Street Analysts Forecast Growth

Several analysts have commented on SNY shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Finally, TD Cowen reissued a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Five equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $62.67.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.